Invertor Relations

 

News Room

METHYLGENE TO PRESENT MGCD265 DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

Preclinical data for MGCD265 demonstrates potent activity in combination with Tarceva® and
against clinically relevant Met mutants

Montreal, Quebec. April 16, 2010 – MethylGene Inc. (TSX:MYG) today announced that there will be two poster presentations describing preclinical data for MGCD265, its proprietary multi-targeted kinase (Met) inhibitor, at the AACR 101st Annual Meeting to be held in Washington, DC from April 17 to 21, 2010. The first abstract (No. 3612) will highlight MGCD265’s in vitro and in vivo antitumor activity when combined with Tarceva®, including against EGFR-resistant tumors. The second abstract (No. 3609) will demonstrate the inhibitory effects of the compound on a spectrum of clinically relevant Met mutants.

Poster Presentations

“Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor”

Tuesday, April 20, 2010 from 9:00am to 12:00pm EDT

Abstract No. 3612

“MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met Mutants”

Tuesday, April 20, 2010 from 9:00am to 12:00pm EDT

Abstract No. 3609

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics with a focus on cancer. The Company’s product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which is nearing completion of Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene’s HDAC platform, EVP-0334 – a potential cognition enhancing agent, is in Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company’s proprietary kinase inhibitor chemistry. Please visit our website at www.methylgene.com.

Investor Relations Contacts

Mark J. Gergen
Executive Vice President & COO
MethylGene Inc.

Tel.: 858 546-2902
ir@methylgene.com
www.methylgene.com

Michael Wood
Managing Director
LifeSci Advisors

Phone: 646 597-6983
mwood@lifesciadvisors.com
www.lifesciadvisors.com

Tracey Rowlands, Ph.D.
Manager, Business and Corporate Development
MethylGene Inc.

Tel.: 514-337-3333 ext. 512
ir@methylgene.com
www.methylgene.com

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene’s control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD265, MGCD290 or mocetinostat (MGCD0103); the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD265, MGCD290 or mocetinostat, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD265, MGCD290 or mocetinostat. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene’s Annual Information Form for the fiscal year ending December 31, 2009, under the heading ”Risk Factors” and all other documents filed by the Company that can be found at www.sedar.com. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

v



About MethylGene.
Our Products.
Investor Relations.

Search

Disclaimer | © MethylGene, 2004-2011.
Website design: Solo Communications